Betrixa 40 Capsule – (40mg)

Square Pharmaceuticals PLC.

Generic: Betrixaban

Weight

0.015 kg

Out of stock

0 People watching this product now!

Indication

Venous Thromboembolism Prevention

Administration

Take with food at approximately the same time each day

Adult Dose

Venous Thromboembolism Prevention Indicated for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for acute medical illness who are at risk for thromboembolic complications owing to moderate or severe restricted mobility and other risk factors for VTE Initial single dose: 160 mg PO, THEN 80 mg PO qDay Recommended duration of treatment: 35-42 days Hepatic impairment Not recommended; drug was not evaluated in hepatic impairment, because these patients may have intrinsic coagulation abnormalities

Renal Dose

Renal impairment Mild-to-moderate (CrCl >30 mL/min): No dose adjustment needed Severe (CrCl >15 to <30 mL/min): Initial single dose of 80 mg, then 40 mg PO qDay x35-42 days

Contraindication

Active pathological bleeding Severe hypersensitivity

Mode of Action

Oral factor Xa (FXa) inhibitor that selectively blocks the active site of FXa and does not require a cofactor (eg, antithrombin III) for activity; inhibits free FXa and prothrombinase activity By directly inhibiting FXa, betrixaban decreases thrombin generation Has no direct effect on platelet aggregation Blood coagulation cascade is dependent upon the activation of factor X to FXa via the intrinsic and extrinsic pathways, which play a central role in the blood coagulation cascade

Precaution

Increases bleeding risk and can cause serious and potentially fatal bleeding; promptly evaluate any signs or symptoms of blood loss; there is no established way to reverse betrixaban’s anticoagulant effect, which can persist for at least 72 hr after the last dose; protamine, vitamin K, and tranexamic acid are not expected to reverse betrixaban anticoagulant activity Risk of paralysis with neuraxial anesthesia Increased bleeding risk with severe renal impairment

Side Effect

1-10% Clinically relevant nonmajor bleeding (2.45%) Epistaxis (2%) Hematuria (2%) <1% Bleeding Major bleeding (0.67%) GI bleeding (0.51%) Intracranial hemorrhage (0.05%) Fatal bleeding (0.03%)

Pregnancy Category Note

Pregnancy No data exist with use in pregnant women, but treatment is likely to increase risk of hemorrhage during pregnancy and delivery Use during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus Animal studies Although betrixaban has not been associated with adverse developmental fetal outcomes in animals, maternal toxicity (ie, hemorrhage) was identified in these studies Lactation Unknown if distributed in human breast milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug…

Interaction

Coadministration with drugs affecting hemostasis increases bleeding risk; examples include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs

-9%Sold out